Background and purpose -Aseptic loosening is a main cause of late revision in total knee replacement (TKR). Teriparatide, a recombinant parathyroid hormone (PTH), stimulates osteoblasts and has been suggested to improve cancellous bone healing in humans. This might also be relevant for prosthesis fi xation. We used radiostereometric analysis (RSA) to investigate whether teriparatide infl uences prosthesis fi xation. Early migration as measured by RSA can predict future loosening.
Background and purpose -Aseptic loosening is a main cause of late revision in total knee replacement (TKR). Teriparatide, a recombinant parathyroid hormone (PTH), stimulates osteoblasts and has been suggested to improve cancellous bone healing in humans. This might also be relevant for prosthesis fi xation. We used radiostereometric analysis (RSA) to investigate whether teriparatide infl uences prosthesis fi xation. Early migration as measured by RSA can predict future loosening.
Patients and methods -In a randomized controlled trial with blind evaluation, 50 patients with osteoarthritis of the knee were allocated to a teriparatide treatment group (Forsteo, 20 µg daily for 2 months postoperatively) or to an untreated control group. RSA was performed postoperatively and at 6 months, 12 months, and 24 months. The primary effect variable was maximal total point motion (MTPM) from 12 to 24 months.
Results -Median maximal total point motion from 12 to 24 months was similar in the 2 groups (teriparatide: 0.14 mm, 10% and 90% percentiles: 0.08 and 0.24; control: 0.13 mm, 10% and 90% percentiles: 0.09 and 0.21). [Authors: this is perhaps better than using "10th" and "90th", which looks ugly in print. /language editor] The 95% confi dence interval for the difference between group means was −0.03 to 0.04 mm, indicating that no difference occurred.
Interpretation -We found no effect of teriparatide on migration in total knee replacement. Other trials using the same dosing have suggested a positive effect of teriparatide on human cancellous fracture healing. Thus, the lack of effect on migration may have been due to something other than the dose. In a similar study in this issue of Acta Orthopaedica, we found that migration could be reduced with denosumab (Ledin et al. 2017) . The difference in response between the anabolic substance teriparatide and the antiresorptive denosumab suggests that resorption has a more important role during the postoperative course than any defi cit in bone formation.
■
Early stable fi xation in total knee replacement (TKR) is important for prevention of late loosening (Ryd et al. 1995 , Pijls et al. 2012 . Radiostereometric analysis (RSA) is performed to estimate fi xation by measuring the postoperative migration of the prosthesis. Bisphosphonates, which are most commonly used in treatment of osteoporosis, have been shown to prevent early migration in TKR (Hilding et al. 2000, Hilding and Aspenberg 2006) and they are associated with a lower risk of revision in epidemiological studies (Teng et al. 2015 , Namba et al. 2016 .
Teriparatide is a recombinant truncated parathyroid hormone (PTH). While bisphosphonates inhibit osteoclast activity, PTH stimulates osteoblasts and acts as an anabolic hormone. In animals, PTH stimulates fracture healing (Andreassen et al. 1999 ) and enhances implant fi xation (Skripitz et al. 2001a ,b, Gabet et al. 2006 , Aspenberg et al. 2008 . Teriparatide stimulates bone formation in osteoporosis treatment, and there are reasons to believe that teriparatide can accelerate fracture healing in clinical settings .
At insertion of a total knee replacement, the metaphyseal bone is traumatized, which is likely to elicit a fracture healing response of a kind typical of metaphyseal injury (Aspenberg 2013 , Bernhardsson et al. 2015 . Since this healing response can be augmented by antiresorptive therapy, we speculated that an anabolic treatment using teriparatide would also augment the process, thereby improving early fi xation in total knee replacement and thus reducing the risk of late loosening.
In this study, we assessed whether teriparatide administered in the postoperative phase can enhance bone healing at the interface between bone and cement after knee replacement surgery. We performed a randomized controlled trial with blind evaluation to study the effects of teriparatide, using migration (by RSA) as the primary effect variable. The specifi c hypothesis was that migration from 12 to 24 months would be reduced, as measured by maximal total point motion (MTPM). This time period was chosen because it appeared to have the best predictive value in the study by Ryd et al. (1995) .
Patients and methods
50 patients (30 women) were included in this 2-center trial. The patients were scheduled for elective cemented primary total knee replacement because of osteoarthritis. 29 of the patients were operated on in Motala and 21 in Oskarshamn, Sweden, and the operations were performed between November 2009 and June 2011. 1 patient (a woman) was excluded because of malignancy diagnosed after surgery. Inclusion criteria were the accepted clinical criteria for elective primary total knee replacement due to primary or secondary osteoarthritis and without severe disease (ASA 1-2). Exclusion criteria were rheumatic arthritis, a history of severe heart disease, renal insuffi ciency, hypercalcemia, metabolic bone disease (osteoporosis was not screened for), malignancy, bilateral surgery, previous radiation therapy of the skeleton, or inability to give informed consent. The patients who declined participation were not registered.
The patients who chose to participate in the study (Table  1) were allocated to treatment by a study nurse who opened a sealed envelope on the fi rst postoperative day. These were prepared by PA using shuffl ing of envelopes before numbering them. Randomization was stratifi ed for sex and performed in blocks of 6 (with some blinded exchange between blocks) which randomized half of the patients to receive subcutaneous teriparatide (Forsteo), 20 µg daily over 2 months postoperatively, starting on the fi rst postoperative day. The other half of the patients received no extra treatment (Figure 1) .
We could not afford to make placebo injection devices, and the patients could not be blinded as to treatment, but evaluation was done blind.
Surgery
The surgery was performed by HL in 29 cases and by 2 other surgeons in 20 cases. All operations were done under spinal anesthesia. We used the Nexgen CR all-poly tibial knee prostheses (Zimmer), which was inserted after pulsed lavage and cemented with Palacos R+G cement (Heraeus Medical AB, Sollentuna, Sweden). 2 g cloxacillin was given just before and twice after the operation. Low-molecular-weight heparin (Innohep, 4,500 IE subcutaneously) was used for 14 postoperative days.
For RSA measurements, 6 tantalum beads (0.8-1.0 mm) were inserted in the all-poly tibial component and 6 in the tibial bone metaphysis. A tourniquet was used during the whole operation.
Evaluation
The radiostereometric examinations were performed on the second postoperative day, and after 6, 12, and 24 months. The analysis of the RSA data was done using the UmRSA computer program (RSA Biomedical AB, Umea, Sweden), by a blinded technician or research nurse.
Statistics
The sample size (n = 50) was calculated from similar studies (Hilding et al. 2000 , Ledin et al. 2012 ) to be able to detect a mean difference in maximum total point motion (MTPM) of 0.2 mm with an SD of 0.2 (α = 0.05 and 80% power).
The primary effect variable was migration measured by RSA (MTPM) during the second year (from 12 to 24 months). The variable was log-transformed. The Kolmogorov-Smirnov test did not reject the hypothesis of normal distribution. Analysis of variance was performed with patient sex and site as covariates. 95% confi dence intervals (CIs) in mm were calculated from the CI for log-transformed values by use of the non-transformed mean value for the controls (values for the ratio of teriparatide/control multiplied by the mean for the control in mm).
Secondary outcomes were other RSA variables. MTPM values were analyzed as above. Other variables were analyzed without transformation. We used IBM SPSS version 23 for statistical calculations.
There were no changes to the protocol.
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Results
The primary effect variable, migration (MTPM from 12 to 24 months), was similar in the 2 groups (median for teriparatide: 0.14 mm, 10% and 90% percentiles: 0.08 and 0.24; median for control: 0.13 mm, 10% and 90% percentiles: 0.09 and 0.21). The 95% confi dence interval for the difference between group means was −0.03 to 0.04 mm (Figure 2) . Migration (MTPM) and other variables showed no significant differences at any time point (Table 2 , see Supplementary data) (Figure 3 ). By comparison with other, similar studies, we especially noted the absence of any substantial difference at 1 year.
The error of measurement for MTPM, based on double examinations in all patients in Motala at 1 year postoperatively (with patients raising between exposures; n = 28) was 0.091 mm (defi ned as SD(diff) × 2 −0.5 × 1.96).
There were no suspected unexpected serious adverse reactions (SUSAR). plays a more important role during the postoperative course than any defi cit in bone formation.
The effects of teriparatide on fracture healing are debated. There have been several studies suggesting a positive effect of the same dose regimen as we used, on radiological healing of wrist fractures (Aspenberg and ) and also on the functional outcome of trochanteric hip fractures (Huang et al. 2015 . However, these results are all based on post hoc testing, and should be interpreted with caution (Aspenberg 2013) . There has also been 1 study on proximal humeral fractures showing no obvious effect of teriparatide (Johansson 2016) .
Prosthesis fi xation has many properties in common with the healing of cancellous bone in metaphyses. Based on human biopsies (Aspenberg and Sandberg 2013) and animal experiments (Bernhardsson et al. 2015) , injured cancellous bone appears to heal by rapid activation of mesenchymal cells present in the bone marrow (Sandberg et al. in press) , and this process responds strongly to PTH in animal models (Skripitz and Aspenberg 2001a,b) . These notions made us believe that teriparatide would improve implant fi xation in humans also.
Our fi ndings regarding migration have rather limited relevance for weighing the evidence for or against a positive effect of teriparatide on fracture healing. Even though we believe that the response to implantation has similarities to cancellous fracture healing, the lavage and cementation creates an environment rather dissimilar to a fracture. In contrast, uncemented prostheses are dependent on the healing response to trauma to produce ingrowth of bone into pores. It is possible that the anabolic effects of teriparatide would have a positive effect here. 
Discussion
Contrary to expectation, we were unable to show any effects of teriparatide treatment on prosthesis migration at any time point. Moreover, the confi dence interval for the difference between group means excluded any meaningful differences. This contrasts with the effect of antiresorptive treatment, which has previously been shown to reduce migration in repeated studies with very much the same design as this one. Moreover, in our accompanying paper (Ledin et al. 2017) , we have shown that another antiresorptive treatment (denosumab) also reduces migration (in the same settings as this study on teriparatide). The difference in response between teriparatide and antiresorptive drugs suggests that resorption Table 2 is available as supplementary data in the online version of this article http://dx.doi.org/10.1080/17453674.2017. 1300745.
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